Keywords: Roche, Rituxanm Follicular lymphoma, Tarceva, Lung cancer, Genentech, Biogen Idec, USA, FDA, Research

Roche gets US FDA approval for Rituxan for follicular lymphoma maintenance; Tarceva meets primary endpoint

Article | 31 January 2011

Print This

Swiss drug major Roche’s (ROG: VX) subsidiary Genentech and Biogen Idec (Nasdaq: BIIB) on Friday received US Food ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in